Answers are grounded in this paper and cite their sources.
Background: Ageing is a gradual biological process characterized by progressive physiological decline and increased susceptibility to age-related diseases. The hallmarks of ageing provide a mechanistic framework for understanding these changes and identifying potential therapeutic targets. Objective: This review summarizes the major hallmarks of ageing, their links to age-related diseases, and pharmacological strategies targeting these mechanisms. Methods: We provide a narrative synthesis of current mechanistic and clinical evidence on candidate gerotherapeutics. Results: Pharmacological interventions targeting nutrient sensing, cellular senescence, mitochondrial dysfunction, and other aging-related pathways include metformin, rapamycin, senotherapeutics, and NAD+ precursors. These agents show potential to improve healthspan and reduce disease burden, although human evidence remains heterogeneous. Conclusion: Targeting the hallmarks of ageing represents a promising therapeutic strategy, but further well-designed clinical studies are needed to establish efficacy, safety, and clinically meaningful benefits.
No takes yet. Share an insight, caveat, or question.
苏琳 et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: